7th Targeted Radiopharmaceuticals Summit EU 2025

Radioligand therapy is evolving rapidly. With new targets like HER2 and FAP coming into focus, and promising data emerging beyond PSMA and SSTR2, there's real momentum building in the field. But to fully unlock the potential of these therapies across Europe, and to integrate RLT as the next pillar of oncology treatment, we need more than scientific innovation. We need collaboration and harmonisation across the entire development journey.

The 7th Targeted Radiopharmaceuticals Summit Europe is here to make that happen.

This is the go-to meeting for anyone working to bring the next generation of targeted radiopharmaceuticals to patients, whether you're involved in early discovery, clinical development, manufacturing, or regulatory affairs. Designed with input from leaders across the RLT space, this year's summit is packed with practical insights, honest conversations, and real-world solutions.

Speakers: Andreas Goutopoulos, CEO, ActiThera, Guido Wuerth, Head Corporate Development, Radiopharma, Affibody AB, Fredrik Frejd, CSO, Affibody AB, Yusuke Kohno, Head of Supply Chain Development, Alpha Fusion Inc., Manuel Sturzbecher-Hoehne, Head of CMC and Radiopharmaceutical Development, Ariceum Therapeutics, Daniel Rossetto, Senior Vice President, Head Of Supply Chain and External Manufacturing, ARTBIO, Bala Nn Rao Attili, Director - Oncology Safety Sciences, AstraZeneca, Mark Fielding, Director, CMC Regulatory Affairs, AstraZeneca, Harshad Kulkarni, Chief Medical Advisor, Bamf Health, Thomas Birger, Edén-Jensen Head of External Supply Management Radiopharmaceuticals, Bayer, Sandra Uhlenbroich, Director, Discovery Project Lead, Bicycle Therapeutics plc, Kemp Dolliver, Senior Director - Research Analyst, Brookline Capital Markets, Jarrod Longcor, Chief Operating Officer, Cellectar Biosciences Inc., Shaemus Gleason, Executive Vice President, Clarity Pharmaceuticals, Setareh Shamsili, Chief Executive Officer and Chief Marketing Officer, Coretag, Angeliki Grammenos, Global Regulatory Affairs Associate Project Lead, Debiopharm, Jeff Cleland, Co-Founder, Iron Fist Therapeutics, Stephen Archibald, Head, Research Department of Imaging Chemistry and Biology, Kings College London, Josefine Reber, Lab Head, Molecular Imaging and RLT, Novartis AG, Isabel Jaco, Senior Principal Scientist and Group leader - Radioligand Therapy Drug Discovery, Novartis AG, Nicoletta Fabiano, Rlt Analytical Development Team Head, Novartis AG, Tim Witney, Chief Scientific Officer, Nuclide Therapeutics, Michael Thiele, Chief Scientific Officer, OncoOne, Oystein Soug, Chief Executive Officer, OncoOne, Volker Wagner, Chief Medical Officer, OranoMed, Julien Torgue, Chief Scientific Officer, OranoMed, Thijs Spoor, Chief Executive Officer, Perspective Therapeutics, Josie Gayton, Chief Operating Officer, Precirix, Vimal Patel, Vice President - Chemistry, Manufacturing and Controls, RadioPharm Theranostics, Levente Meszaros, Head, Clinical Operations and Programs, RadioPharm Theranostics, John Babich, President and Chief Scientific Officer, Ratio Therapeutics, Catello Somma, Partner, Seroba Life Sciences, Abbas El Sahil,i Chief Executive Officer, Singzyme, Sigal Cusnir, CEO, Starget Pharma, Jeremy Paull, Chief Scientific and Regulatory Officer, Starpharma Ltd., Frederic Fantino, Senior Director - Medical, Telix Pharmaceuticals, Anil Lalwani, Director - Regulatory CMC and MedTech, Telix Pharmaceuticals, Arthur Braat, Associate professor 'Translational Nuclear Oncology', Nuclear Medicine Physician, UMC Utrecht, Luke Brzozowski, Executive Director, Theranostics and Core Facilities, University Health Network, Stuart More, Head of Department - Nuclear Medicine, University of Cape Town, Rebecca Ferissi, Postdoctoral Researcher, University of Milan, Labros Meimetis, Research Assistant Professor, University of Wisconsin, School of Medicine and Public Health, Brian H Santich, Vice President, Research, Y-mAbs Therapeutics Inc